Roivant Sciences Offloads Psoriasis Medicine Maker To Organon ...
WEB2 days ago · Psoriasis is a common chronic inflammatory skin disease affecting over 8 million Americans 20 years or older and 125 million people worldwide. Organon has agreed to acquire Dermavant for aggregate ...
Roivant sells dermatology spinoff to Organon in deal worth $1 ...
WEB1 day ago · Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion. Organon is buying ...
News & Press Releases | Roivant
WEBJul 19, 2024 · Financially, Roivant is well-capitalized with $6.67 billion in cash against minimal liabilities. Investment recommendation: Buy Roivant as part of a high-risk segment of a diversified portfolio. Roivant spinoff tackles growing complexity of clinical trials.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to ...
WEB2 days ago · Resize. By Colin Kellaher. Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on ...
Organon to Acquire Dermavant including its Innovative ...
WEB1 day ago · BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a ...
Press Releases - Roivant Sciences Ltd.
WEB2 days ago · Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million. February 13, 2024.
Roivant
WEBApr 2, 2024 · Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million. Read the …
Roche Enters Into a Definitive ... - Roivant Sciences Ltd.
WEBOct 23, 2023 · BASEL, Switzerland and LONDON and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the entry into a definitive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.
Roivant and Pfizer Form New Vant Company Focused on ...
WEBDec 1, 2022 · A new Vant or Roivant subsidiary has been created to develop and fund these programs. The Vant will be fully responsible for funding global development of RVT-3101 in UC and in additional inflammatory and fibrotic diseases and holds commercial rights in the US and Japan.
Roivant Sciences Ltd. (ROIV) Latest Stock News & Headlines ...
WEBGet the latest Roivant Sciences Ltd. (ROIV) stock news and headlines to help you in your trading and investing decisions.
Skip to content